Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort studyObservational Study Published on 2022-09-012022-10-05 Journal: Respiratory Research [Category] SARS, 임상, 진단, [키워드] addition age and sex Anti-inflammatory Anti-inflammatory therapy anti-inflammatory treatments Anti-spike antibody Antibody titer antifibrotic therapy BNT162b2 BNT162b2 vaccine caused Cohort conducted control group dose evaluate evaluated healthy control high risk humoral Humoral response ILD immune response Immunosuppression Interstitial lung disease IPF maintain median Messenger RNA Patient patients patients treated patients with ILD prospective cohort study pulmonary fibrosis Rabin Medical Center SARS-CoV-2 vaccine serology test seronegative seropositive Severe COVID-19 Infection significantly lower the healthy therapy treated Treatment vaccination vaccine dose was reduced [DOI] 10.1186/s12931-022-02155-x PMC 바로가기 [Article Type] Observational Study
Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based reviewCOVID-19 예방접종 후 항MDA5 피부근염: 사례 기반 검토Review Published on 2022-09-012022-09-12 Journal: Rheumatology International [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] activated administration characterized COVID-19 COVID-19 infection COVID-19 vaccine COVID-19 vaccines cytosolic dendritic cell dermatomyositis downstream epithelial cells erythematous Evidence high risk IFN individual inflammatory mediator Interstitial lung disease lesion literature review lung MDA5 MDA5. mRNA NAT Protein receiving replicate reported SARS-CoV-2 shown Trigger triggered type 1 interferon ulcerative vaccination Vaccine worldwide pandemic [DOI] 10.1007/s00296-022-05149-6 PMC 바로가기 [Article Type] Review
A case of adenoviral covid-19 vector vaccine possibly linked to severe but reversible interstitial lung injury post-vaccinationCase Reports Published on 2022-09-012023-07-09 Journal: Infectious diseases (London, England) [Category] COVID19(2023년), [키워드] Adenoviral nCoV-19 vector vaccine adverse-reactions AZD1222 glucocorticosteroids treatment Interstitial lung disease steroid pulses. [DOI] 10.1080/23744235.2022.2072521 [Article Type] Case Reports
Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter studyObservational Study Published on 2022-08-012022-10-05 Journal: Seminars in arthritis and rheumatism [Category] 임상, [키워드] 95% CI age Analysis Cohort cohort of patient Comorbidity cough COVID-19 COVID-19 in patient death deaths diagnosed with COVID-19 disease Dyspnea evaluate FVC Gender greater higher risk highly suspicious infection Hospitalization impacted Infection Interstitial lung disease lung Lung disease Mild moderate-to-severe COVID-19 Mortality multicenter need for oxygen outcome Patient patients patients with COVID-19 positive RT-PCR predictor presenting Prevalence pulmonary arterial hypertension remained retrospective severity significantly Support Symptom systemic Systemic sclerosis the patient Treatment Univariate analysis use of corticosteroids [DOI] 10.1016/j.semarthrit.2022.151987 PMC 바로가기 [Article Type] Observational Study
Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung diseaseClinical Trial Published on 2022-07-232022-10-05 Journal: Orphanet Journal of Rare Diseases [Category] COVID19(2023년), SARS, 임상, [키워드] absence adverse event age all subject approval ARMS calculated Child childhood children Controlled trial double-blind effect size Endpoint evaluated four subject groups HCQ Health Hydroxychloroquine identify Interstitial lung disease Interstitial lung diseases lack lung Lung function multicentre Munich not differ not different offered outcome Oxygenation participated phase 2 trial Placebo placebo-controlled primary endpoint Pulmonary function Quality of life Randomized randomized-controlled trial Registered Registration respiratory rate Respiratory Support secondary study population subject Treatment treatment effects treatment period Trial university were given Withdrawal [DOI] 10.1186/s13023-022-02399-2 PMC 바로가기 [Article Type] Clinical Trial
Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases조직간 단세포 기질 아틀라스는 4가지 만성 염증성 질환에서 공유된 병리학적 섬유아세포 표현형을 식별합니다.Article Published on 2022-07-082022-09-11 Journal: Med (New York, N.Y.) [Category] 비임상, [키워드] Activation affected animal model animal models Arthritis atlas atopic dermatitis breath CCL19 chronic inflammatory disease chronic inflammatory diseases Clusters COL3A1 Critical CXCL10 disease Diseases donors exacerbated fibroblast fibroblasts Foundational research heterogeneity Hoffmann-La Roche identify immune individual inflamed tissue Inflammation Inflammatory bowel disease Inflammatory diseases integration interstitial Interstitial lung disease intestinal inflammation intestine joint lack lung Lung disease Lungs mapped organ systems Pathogenesis pathogenic pathway Pathways phenotype Phenotypes pro-inflammatory reveal rheumatoid arthritis Roche salivary gland salivary glands scRNA-seq single-cell Single-cell RNA sequencing Sjögren's syndrome SPARC stromal syndrome synovium therapeutic target ulcerative colitis [DOI] 10.1016/j.medj.2022.05.002 PMC 바로가기 [Article Type] Article
A 51-Year-Old Woman With Interstitial Lung Disease and Subsequent COVID-19 Presenting With Worsening DyspneaCase report Published on 2022-07-062022-10-05 Journal: Chest [Category] 변종, 유전자 메커니즘, [키워드] airway BAL bronchoscopy Care Chest CT COVID-19 cultures defined Diagnosis diffusing Dyspnea foamy macrophage foamy macrophages functional ground-glass opacity Hospitalization Hospitalized ILD impairment Inconclusive interlobular septal thickening Interstitial lung disease intralobular lung Lung disease Mild Moderate COVID-19 Patient presentation presenting Pulmonary function testing Result Shortness of breath specimen table transbronchial transfer video-assisted thoracoscopic surgery woman worsening [DOI] 10.1016/j.chest.2022.01.059 [Article Type] Case report
Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) StudyObservational Study Published on 2022-07-012022-10-05 Journal: BMJ Open Respiratory Research [Category] COVID19(2023년), SARS, 임상, [키워드] analysed approval baseline data Care Characteristics Clinical course clinical phenotype Comorbidities Control COVID-19 COVID-19 pandemic determine Ethics event Factor Features follow-up period General population group higher risk Host illness Impact include Infection Infectious disease Interstitial Fibrosis Interstitial lung disease intervals Local Lung function measure Non-COVID-19 non-infected outcome outcomes Patient patients Prospective Study pulmonary sarcoidosis Quality of life rationale recorded recruitment required respiratory respiratory infections respiratory pathogen respiratory viral sarcoidosis SARS-CoV-2 severity study cohort survival trajectory USA viral infection [DOI] 10.1136/bmjresp-2022-001254 PMC 바로가기 [Article Type] Observational Study
Contemporary Concise Review 2021: Interstitial lung diseaseReview Published on 2022-07-012023-07-09 Journal: Respirology (Carlton, Vic.) [Category] COVID19(2023년), [키워드] fibroblast fibrosis Interstitial lung disease lung respiratory [DOI] 10.1111/resp.14278 PMC 바로가기 [Article Type] Review
Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs항염증제 및 항바이러스제 치료를 받는 간질성 폐질환 환자의 코로나19 결과Article Published on 2022-07-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] 치료제, [키워드] Affect age and sex anti-inflammatory drug antiviral drug antiviral drugs Antiviral treatment coronavirus disease Coronavirus disease 2019 Corticosteroid corticosteroid therapy Corticosteroids COVID-19 COVID-19 patient COVID-19 patients death Diagnosis evaluate Favipiravir fibrosis honeycomb lung HRCT Idiopathic pulmonary fibrosis ILD immunosuppressive agent Immunosuppressive agents increased risk Interstitial lung disease interstitial pneumonia lung Lung disease medical record medical records mortality rate no statistical difference outcome Patient patients treated patients with COVID-19 proportion pulmonary fibrosis Remdesivir reported risk factor Risk factors selected severe disease Severe patient severe patients treated Univariate analysis [DOI] 10.1016/j.jiac.2022.04.006 PMC 바로가기 [Article Type] Article